Article
Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo.
JNCI cancer spectrum - 1 Oct 2021
Goodwin Pamela J, Dowling Ryan J O, Ennis Marguerite, Chen Bingshu E, Parulekar Wendy R, Shepherd Lois E, Gelmon Karen A, Whelan Timothy J, Ligibel Jennifer A, Hershman Dawn L, Mayer Ingrid A, Hobday Timothy J, Rastogi Priya, Rabaglio-Poretti Manuela, Lemieux Julie, Thompson Alastair M, Rea Daniel W, Stambolic Vuk
Abstract excerpt
Background: Circulating levels of cancer antigen (CA) 15-3, a tumor marker and regulator of cellular metabolism, were reduced by metformin in a nonrandomized neoadjuvant study. We examined the effects of metformin (vs placebo) on CA 15-3 in participants of MA.32, a phase III randomized trial in early-stage breast cancer. Methods: A total of 3649 patients with T1-3, N0-3, M0 breast cancer were randomly assigned;...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.